1138 GMT - European defense and pharmaceutical stocks are expected to perform strongly beyond 2025, Moody's analysts Martin Kohlhase and Marina Albo say in a note to investors. Europe's defense companies continue to benefit from structural demand drivers that are unlikely to abate in the next years, they say. Their order books are strong and cover between two and five years of revenue, they write. Global supply-chain challenges affecting aerospace and defense companies pose the main risk to Moody's double-digit percentage operating profit growth forecast for 2025, they note. Meanwhile, demand for weight-loss and diabetes drugs as well as the strong growth of oncology and immunology treatments should keep pharmaceutical stocks high, the analysts say. (cristina.gallardo@wsj.com)
(END) Dow Jones Newswires
November 20, 2024 06:40 ET (11:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。